{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:22Z","timestamp":1793915302689,"version":"4.8.0"},"reference-count":48,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/na","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeted radionuclide therapy (TRT) with 177Lu holds a huge clinical success in treating advanced prostate cancer patients. It is noted, however, that 177Lu with moderate radiation energy achieves effective tumor inhibition at a relatively high dose and has a low capacity to activate \u201ccold\u201d prostate tumor. In this study, we report that Sigma-1 receptor and prostate-specific membrane antigen (PSMA) dual-targeted peptide (S1R\/PSMA-P) labeled with 161Tb, which emits locally high linear energy transfer (LET) Auger electrons, effectively inhibits prostate tumor and energizes anticancer immunity. 161Tb\u2013S1R\/PSMA-P exhibited significantly enhanced cytotoxicity and immunogenic cell death over 177Lu-labeled counterpart by inducing more DNA double-strand breaks and reactive oxygen species. Of note, 161Tb\u2013S1R\/PSMA-P achieved high tumor uptake and selectivity, induced a complete regression rate of 60% at a single dose of 7.4 MBq in RM1-PSMA+\/RM1 tumor model, and sensitized RM1-PSMA+\/RM1 tumor to \u03b1PD1 immune checkpoint blockade therapy at a dose of 3.7 MBq resulting in a cure rate of 50% and durable antitumor immunity. Overall, 161Tb\u2013S1R\/PSMA-P emerges as a promising theranostic agent that is capable of mitigating prostate tumor by boosting anticancer immunity.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00650","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:20:47Z","timestamp":1783095647000},"page":"4311-4321","source":"Crossref","is-referenced-by-count":1,"title":["Dual-Targeted\nRadionuclide Therapy with 161Tb Instigates Anticancer Immunity\nin \u201cCold\u201d Murine\nProstate Tumor"],"prefix":"10.1021","volume":"23","author":[{"given":"Juan","family":"Sun","sequence":"first","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakun","family":"Guo","sequence":"additional","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunhao","family":"Qi","sequence":"additional","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Yang","sequence":"additional","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-119X","authenticated-orcid":true,"given":"Guanglin","family":"Wang","sequence":"additional","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5695-2308","authenticated-orcid":true,"given":"Guangming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8608-7738","authenticated-orcid":true,"given":"Fenghua","family":"Meng","sequence":"additional","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-4741","authenticated-orcid":true,"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Soochow University , , ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"7","key":"2026080309072696800_cit1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41587-024-02295-z","article-title":"Precision\nradiation opens a new window on cancer therapy","volume":"42","author":"Senior","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"2026080309072696800_cit2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics\nin oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"2026080309072696800_cit3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3322\/caac.21768","article-title":"Radiotheranostics\nin oncology: making\nprecision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"Ca-Cancer J. Clin."},{"key":"2026080309072696800_cit4","doi-asserted-by":"publisher","first-page":"114538","DOI":"10.1016\/j.addr.2022.114538","article-title":"Imaging-guided\ntargeted radionuclide tumor therapy:\nfrom concept to clinical translation","volume":"190","author":"Sun","year":"2022","journal-title":"Adv. Drug\nDelivery Rev."},{"issue":"9","key":"2026080309072696800_cit5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/s43018-023-00619-7","article-title":"Harnessing\nprogress in radiotherapy for global cancer control","volume":"4","author":"Jaffray","year":"2023","journal-title":"Nat. Cancer"},{"issue":"9","key":"2026080309072696800_cit6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating\nthe theranostic concept to neuro-oncology: Disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026080309072696800_cit7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2023.03.001","article-title":"Next generation\nradiotheranostics promoting precision medicine","volume":"34","author":"Pomykala","year":"2023","journal-title":"Ann. Oncol."},{"issue":"7","key":"2026080309072696800_cit8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","article-title":"Assessment of therapy-related myeloid\nneoplasms in patients with neuroendocrine tumors after peptide receptor\nradionuclide therapy: a systematic review","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA\nOncol"},{"issue":"2","key":"2026080309072696800_cit9","doi-asserted-by":"publisher","first-page":"220859","DOI":"10.1148\/radiol.220859","article-title":"177Lu-Prostate-specific\nmembrane\nantigen radioligand therapy in patients with metastatic castration-resistant\nprostate cancer","volume":"306","author":"Parihar","year":"2023","journal-title":"Radiology"},{"issue":"2","key":"2026080309072696800_cit10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for\nmidgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"2026080309072696800_cit11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse\nevents of actinium-225-PSMA-617 in advanced metastatic castration-resistant\nprostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur. Urol."},{"issue":"11","key":"2026080309072696800_cit12","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","article-title":"Advances in\ntargeted alpha therapy for prostate cancer","volume":"30","author":"De Vincentis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"2026080309072696800_cit13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00259-024-06658-1","article-title":"Advances in targeted alpha therapy of cancer","volume":"51","author":"Sathekge","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5546","key":"2026080309072696800_cit14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.1064126","article-title":"Tumor therapy\nwith targeted atomic nanogenerators","volume":"294","author":"McDevitt","year":"2001","journal-title":"Science"},{"key":"2026080309072696800_cit15","doi-asserted-by":"publisher","first-page":"118053","DOI":"10.1016\/j.trac.2024.118053","article-title":"Recent advances\nin emerging radiopharmaceuticals and the challenges in radiochemistry\nand analytical chemistry","volume":"182","author":"Ding","year":"2025","journal-title":"TrAC, Trends Anal.\nChem."},{"issue":"5","key":"2026080309072696800_cit16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2967\/jnumed.124.267611","article-title":"Is 161Tb\nreally happening?","volume":"65","author":"Kong","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"4","key":"2026080309072696800_cit17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin\nreceptor antagonists-a potential paradigm shift for the treatment\nof neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med.\nMol. Imaging"},{"issue":"1","key":"2026080309072696800_cit18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40658-023-00589-w","article-title":"Replacing\nLu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric\nimplications for activity selection","volume":"10","author":"Verburg","year":"2023","journal-title":"EJNMMI\nPhys."},{"issue":"1","key":"2026080309072696800_cit19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from\n161Tb and 177Lu in single tumour\ncells and micrometastases","volume":"7","author":"Alcocer-Avila","year":"2020","journal-title":"EJNMMI Phys."},{"issue":"1","key":"2026080309072696800_cit20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","article-title":"Prostate cancer\nmicroenvironment: multidimensional regulation of immune cells, vascular\nsystem, stromal cells, and microbiota","volume":"23","author":"Chen","year":"2024","journal-title":"Mol.\nCancer"},{"issue":"8048","key":"2026080309072696800_cit21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy\nresistance in prostate\ncancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"issue":"1","key":"2026080309072696800_cit22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/imr.13263","article-title":"Using immunogenic\ncell death to improve anticancer\nefficacy of immune checkpoint inhibitors: From basic science to clinical\napplication","volume":"321","author":"Ghiringhelli","year":"2024","journal-title":"Immunol. Rev."},{"key":"2026080309072696800_cit23","doi-asserted-by":"publisher","first-page":"216167","DOI":"10.1016\/j.canlet.2023.216167","article-title":"Improvement strategy for immune checkpoint\nblockade: a focus on the combination with immunogenic cell death inducers","volume":"562","author":"Shi","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"2026080309072696800_cit24","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/s41467-026-68834-1","article-title":"Priming\nversus propagating: distinct immune effects of alpha- versus beta-particle\nemitting radiopharmaceuticals when combined with immune checkpoint\ninhibition in mice","volume":"17","author":"Kerr","year":"2026","journal-title":"Nat. Commun."},{"issue":"8015","key":"2026080309072696800_cit25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands\npotentiate\nradionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"issue":"15","key":"2026080309072696800_cit26","doi-asserted-by":"publisher","first-page":"13392","DOI":"10.1021\/acs.jmedchem.4c01295","article-title":"Molecular\nevolution of multivalent\nOncoFAP derivatives with enhanced tumor uptake and prolonged tumor\nretention","volume":"67","author":"Galbiati","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026080309072696800_cit27","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1021\/acs.bioconjchem.2c00209","article-title":"IgG-binding nanobody\ncapable of prolonging nanobody-based radiotracer plasma half-life\nand enhancing the efficacy of tumor-targeted radionuclide therapy","volume":"33","author":"Hu","year":"2022","journal-title":"Bioconjugate Chem."},{"key":"2026080309072696800_cit28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jconrel.2024.09.040","article-title":"PSMA and Sigma-1\nreceptor dual-targeted peptide mediates superior radionuclide imaging\nand therapy of prostate cancer","volume":"375","author":"Huangfu","year":"2024","journal-title":"J. Controlled\nRelease"},{"key":"2026080309072696800_cit29","doi-asserted-by":"publisher","first-page":"113686","DOI":"10.1016\/j.jconrel.2025.113686","article-title":"Dual-targeted\nalpha\ntherapy mitigates prostate cancer and boosts immune checkpoint blockade\ntherapy","volume":"382","author":"Sun","year":"2025","journal-title":"J. Controlled Release"},{"key":"2026080309072696800_cit30","doi-asserted-by":"publisher","first-page":"114945","DOI":"10.1016\/j.colsurfb.2025.114945","article-title":"Naphthalene-containing\noctreotide radioligand elevates selectivity and radionuclide therapy\nfor somatostatin receptor 2-positive tumor","volume":"255","author":"Sun","year":"2025","journal-title":"Colloid Surf. B-Biointerfaces"},{"issue":"11","key":"2026080309072696800_cit31","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","article-title":"Establishing\n(177)Lu-PSMA-617 radioligand therapy in a syngeneic model of murine\nprostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"key":"2026080309072696800_cit32","doi-asserted-by":"publisher","first-page":"114003","DOI":"10.1016\/j.jconrel.2025.114003","article-title":"Oncolytic\nmicrogels with regulated antibody release augment tumor\nimmunotherapy","volume":"385","author":"Guo","year":"2025","journal-title":"J. Controlled Release"},{"issue":"10","key":"2026080309072696800_cit33","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","article-title":"Albumin-binding\nand conventional PSMA ligands in combination with (161)Tb: biodistribution,\ndosimetry, and preclinical therapy","volume":"64","author":"Tschan","year":"2023","journal-title":"J. Nucl.\nMed."},{"issue":"5","key":"2026080309072696800_cit34","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.7150\/thno.92273","article-title":"[(161)Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC:\npreliminary dosimetry results and intra-individual head-to-head comparison\nto [(177)Lu]Lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics"},{"issue":"8","key":"2026080309072696800_cit35","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2967\/jnumed.122.265291","article-title":"Tb-PSMA radioligand\ntherapy: first-in-humans SPECT\/CT imaging","volume":"64","author":"Al-Ibraheem","year":"2023","journal-title":"J.\nNucl. Med."},{"issue":"10","key":"2026080309072696800_cit36","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2967\/jnumed.120.258376","article-title":"First-in-humans application of (161)Tb: a feasibility\nstudy using (161)Tb-DOTATOC","volume":"62","author":"Baum","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026080309072696800_cit37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","article-title":"Albumin-binding\nPSMA ligands: optimization of the tissue distribution profile","volume":"15","author":"Benes\u030cova\u0301","year":"2018","journal-title":"Mol. Pharmaceutics"},{"issue":"3","key":"2026080309072696800_cit38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2967\/jnumed.123.266233","article-title":"Preclinical\nevaluation of gastrin-releasing peptide receptor antagonists labeled\nwith 161Tb and 177Lu: a comparative study","volume":"65","author":"Holzleitner","year":"2024","journal-title":"J.\nNucl. Med."},{"issue":"12","key":"2026080309072696800_cit39","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2967\/jnumed.125.270952","article-title":"Initial multicenter experience with\n161Tb-PSMA in 177Lu-PSMA\u2013refractory\nmetastatic castration-resistant prostate cancer: preliminary results","volume":"66","author":"Kucuk","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"11","key":"2026080309072696800_cit40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41585-024-00924-5","article-title":"Immune effects\nof \u03b1 and \u03b2\nradionuclides in metastatic prostate cancer","volume":"21","author":"Lunj","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"2026080309072696800_cit41","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1007\/s00259-025-07293-0","article-title":"Efficacy\nof combined\ntargeted radionuclide therapy and immune checkpoint Inhibition in\nanimal tumour models: a systematic review and meta-analysis of the\nliterature","volume":"52","author":"Kleinendorst","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026080309072696800_cit42","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jconrel.2023.08.026","article-title":"Remodeling tumor immunosuppression\nwith molecularly imprinted nanoparticles to enhance immunogenic cell\ndeath for cancer immunotherapy","volume":"362","author":"He","year":"2023","journal-title":"J. Controlled\nRelease"},{"issue":"17","key":"2026080309072696800_cit43","doi-asserted-by":"publisher","first-page":"11070","DOI":"10.1021\/acsnano.3c11464","article-title":"Dual-responsive nanomedicine activates\nprogrammed antitumor immunity through targeting lymphatic system","volume":"18","author":"Xiao","year":"2024","journal-title":"ACS Nano"},{"issue":"6","key":"2026080309072696800_cit44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2967\/jnumed.124.268805","article-title":"161Tb radioimmunotherapy\nas a treatment for CD30-positive lymphomas","volume":"66","author":"Rioja-Blanco","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026080309072696800_cit45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12943-026-02636-3","article-title":"Calibrating\nthe RT-cGAS-STING axis\nto drive cold-to-hot tumor transformation: mechanistic foundations\nand translational strategies for combination with immunotherapy","volume":"25","author":"Kang","year":"2026","journal-title":"Mol. Cancer"},{"issue":"3","key":"2026080309072696800_cit46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013732","article-title":"Fluorination augments tumor engagement\nand antitumor immunity of\na D-peptide-based radiotheranostic agent for combinatorial immune\ncheckpoint blockade therapy","volume":"14","author":"Zhang","year":"2026","journal-title":"J. Immunother.\nCancer"},{"issue":"11","key":"2026080309072696800_cit47","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41590-022-01338-4","article-title":"Shared and distinct\nbiological circuits in effector, memory and exhausted CD8+ T cells\nrevealed by temporal single-cell transcriptomics and epigenetics","volume":"23","author":"Giles","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"2026080309072696800_cit48","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1038\/s41467-024-50345-6","article-title":"Cytomegalovirus\nvaccine vector-induced effector memory CD4 + T cells protect cynomolgus\nmacaques from lethal aerosolized heterologous avian influenza challenge","volume":"15","author":"Malouli","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00650","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4311\/65678557\/acs.molpharmaceut.6c00650.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4311\/65678557\/acs.molpharmaceut.6c00650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:21:37Z","timestamp":1785763297000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4311\/5193960\/Dual-Targeted-Radionuclide-Therapy-with-161Tb"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00650","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}